Close Menu

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA and insurer Anthem have issued positive coverage decisions for Myriad Genetics' breast cancer recurrence test EndoPredict, the company announced.

“We now have nearly full coverage for EndoPredict testing in the United States which was accomplished in an unprecedented time of less than six months after our launch,” Myriad CEO Mark Capone said in a statement. Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.